The cost-effectiveness and public health benefit of nalmefene added to psychosocial support for the reduction of alcohol consumption in alcohol-dependent patients with high/very high drinking risk levels: A Markov model

BMJ Open

Volumn 4, Issue 9, 2014, Pages

  Laramée, Philippe ^a,b   Brodtkorb, Thor Henrik ^c   Rahhali, Nora ^b   Knight, Chris ^d   Barbosa, Carolina ^e   Franҫois, Clément ^b   Toumi, Mondher ^a   Daeppen, Jean Bernard ^f   Rehm, Jürgen ^g,h,i  

^a UNIVERSITÉ LYON 1   (France)

^b Lundbeck   (France)

^c RTI HEALTH SOLUTIONS   (United States)

^d BRESMED   (United Kingdom)

^e RTI INTERNATIONAL   (United States)

^f LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^g CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^h UNIVERSITY OF TORONTO   (Canada)

ⁱ DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

NALMEFENE; PLACEBO; NALTREXONE;

ADULT; ALCOHOL CONSUMPTION; ALCOHOLISM; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DETOXIFICATION; DRINKING BEHAVIOR; DRUG COST; DRUG EFFECT; FEMALE; FOLLOW UP; HEALTH STATUS; HUMAN; INCIDENCE; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORBIDITY; MORTALITY; NATIONAL HEALTH SERVICE; PROBABILITY; PSYCHOSOCIAL CARE; PUBLIC HEALTH INSURANCE; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY ANALYSIS; TREATMENT DURATION; UNITED KINGDOM; ANALOGS AND DERIVATIVES; COST BENEFIT ANALYSIS; ECONOMICS; MULTIMODALITY CANCER THERAPY; PREVENTION AND CONTROL; PUBLIC HEALTH; RISK ASSESSMENT; SOCIAL SUPPORT;

ALCOHOL DRINKING; ALCOHOLISM; COMBINED MODALITY THERAPY; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; MALE; MARKOV CHAINS; MIDDLE AGED; NALTREXONE; PUBLIC HEALTH; RISK ASSESSMENT; SOCIAL SUPPORT;

EID: 84907212093     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2014-005376     Document Type: Article

References (47)

1. Dawson DA, Hingson RW, Grant BF. Epidemiology of alcohol use, abuse and dependence. 3rd edn. Textbook in Psychiatric Epidemiology, 2011:361-79.
2. Rehm J, Mathers C, Popova S, et al. Global burden of disease and injury and economic cost attributable to alcohol use and alcohol-use disorders. Lancet 2009;373:2223-33.
3. Lim S, Vos T. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;380:2224-60.
4. World Health Organization (WHO). Global status report on alcohol 2004. Geneva: World Health Organization, 2004.
5. Rehm J, Baliunas D, Borges GL, et al. The relation between different dimensions of alcohol consumption and burden of disease: an overview. Addiction 2010;105:817-43.
6. Rehm J, Zatonksi W, Taylor B, et al. Epidemiology and alcohol policy in Europe. Addiction 2011;106(Suppl 1):11-19.
7. Rehm J, Shield K, Gmel G, et al. Modeling the impact of alcohol dependence on mortality burden and the effect of available treatment interventions in the European Union. Eur Neuropsychopharmacol 2013;23:89-97.
8. National Institute for Health and Care Excellence (NICE). Clinical Guidelines (CG115) Alcohol dependence and harmful alcohol use, 2011.
9. National Institute for Health and Care Excellence (NICE). Public Health Guidance (PH24) Alcohol-use disorders - preventing harmful drinking, 2010.
10. European Medicines Agency (EMA). Guideline on the development of medicinal products for the treatment of alcohol dependence, 2010.
11. Committee for Medicinal Products for Human Use (CHMP). European public assessment report: Nalmefene. Updated: 04/02/2014, 2013.
12. Michel M, Bolger G, Weissman B. Binding of a new opiate antagonist, nalmefene, to rat brain membranes. Methods Find Exp Clin Pharmacol 1985;7:175.
13. Nealey KA, Smith AW, Davis SM, et al. κ-opioid receptors are implicated in the increased potency of intra-accumbens nalmefene in ethanol-dependent rats. Neuropharmacology 2011;61:35-42.
14. van den Brink W, Aubin H-J, Bladström A, et al. Efficacy of as-needed nalmefene in alcohol-dependent patients with at least a high drinking risk level: results from a subgroup analysis of two randomized controlled 6-month studies. Alcohol Alcohol 2013;48:570-78.
15. van den Brink W, Sørensen P, Torup L, et al. for the SENSE Study Group. Long-term efficacy, tolerability and safety of nalmefene as-needed in patients with alcohol dependence: a 1-year, randomised controlled study. J Psychopharmacol 2014;28:733-44.
16. World Health Organization (WHO). International guide for monitoring alcohol consumption and related harm. Department of Mental Health and Substance Dependence, Noncommunicable Diseases and Mental Health Cluster, 2000.
17. Purshouse RC, Meier PS, Brennan A, et al. Estimated effect of alcohol pricing policies on health and health economic outcomes in England: an epidemiological model. Lancet 2010;375:1355-64.
18. The Scottish Government. Minimum Pricing.
19. Sheffield University. Modelling to assess the effectiveness and cost-effectiveness of public health related strategies and interventions to reduce alcohol attributable harm in England using the Sheffield Alcohol Policy Model, version 2.0, 2009.
20. Scottish Medicines Consortium (SMC). Advice 917/13 nalmefene (Selincro), 2013.
21. All Wales Medicines Strategy Group (AWMSG). Nalmefene (Selincro®). Reference No.1259, 2014.
22. National Institute for Health and Care Excellence (NICE). Nalmefene for reducing alcohol consumption in people with alcohol dependence: appraisal consultation document [ID660] 2014.
23. National Institute for Health and Care Excellence (NICE). Nalmefene for reducing alcohol consumption in people with alcohol dependence: publication date. Secondary Nalmefene for reducing alcohol consumption in people with alcohol dependence: publication date 2014. http://www.nice.org.uk/Guidance/InDevelopment/gid-tag442
24. Starosta AN, Leeman RF, Volpicelli JR. The BRENDA model: integrating psychosocial treatment and pharmacotherapy for the treatment of alcohol use disorders. J Psychiatr Pract 2006;12:80.
25. electronic Medicines Compendium (eMC). Summary of Product Characteristics: Selincro 18 mg tablets. Updated 24 Jan 2013.
26. Barbosa C, Taylor B, Godfrey C, et al. Modelling lifetime QALYs and health care costs from different drinking patterns over time: a Markov model. Int J Methods Psychiatr Res 2010;19:97-109.
27. Taylor C, Brown D, Duckitt A, et al. Patterns of outcome: drinking histories over ten years among a group of alcoholics. Br J Addict 1985;80:45-50.
28. Rehm J, Shield KD, Rehm MX, et al. Alcohol consumption, alcohol dependence and attributable burden of disease in Europe. Centre for Addiction and Mental Health, 2012.
29. Rehm J, Scafato E. Indicators of alcohol consumption and attributable harm for monitoring and surveillance in European Union countries. Addiction 2011;106:4-10.
30. Taylor B, Rehm J, Room R, et al. Determination of lifetime injury mortality risk in Canada in 2002 by drinking amount per occasion and number of occasions. Am J Epidemiol 2008;168:1119-25.
31. National Institute for Health and Care Excellence (NICE). Clinical Guidelines (CG100) Alcohol-use disorders: physical complications, 2010:215.
32. Rome A. Deconstructing BRENDA: an identification of the components of psychosocial support and their utility.
33. National Health Service (NHS) reference cost database 2010-2011; Elective Inpatient HRG Data; Currency Code DZ11A, DZ11B, DZ11C, DZ23A, DZ23B, DZ23C.
34. Personal Social Services Research Unit (PSSRU). Unit costs of Health and social care, 2011.
35. National Institute for Health and Care Excellence (NICE). Specification for manufacturer/sponsor submission for Single Technology Appraisal (STA), 2009.
36. MIMS. Selincro (POM), 2014.
37. Sisk JE, Whang W, Butler JC, et al. Cost-effectiveness of vaccination against invasive pneumococcal disease among people 50 through 64 years of age: role of comorbid conditions and race. Ann Intern Med 2003;138:960-68.
38. Cardiff Research Consortium. Health Outcomes Data Repository (HODaR), 2008.
39. Doubilet P, Begg CB, Weinstein MC, et al. Probabilistic sensitivity analysis using Monte Carlo simulation. A practical approach. Med Decis Making 1984;5:157-77.
40. Briggs AH, Claxton K, Sculpher MJ. Decision modelling for health economic evaluation. Oxford university press, 2006.
41. Briggs AH, Weinstein MC, Fenwick EA, et al. Model parameter estimation and uncertainty analysis a report of the ISPOR-SMDM Modeling Good Research Practices Task Force Working Group-6. Med Decis Making 2012;32:722-32.
42. Coste F, Chalem Y, Franc¸ois C, et al. Naturalistic Disease Management Study of Patients with Alcohol Dependence in the Primary Care Setting in the United Kingdom (STREAM). Value Health 2013;16:A551.
43. Eddy DM, Hollingworth W, Caro JJ, et al. Model transparency and validation a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-7. Med Decis Making 2012;32:733-43.
44. National Institute for Health and Care Excellence (NICE). Guide to the methods of technology appraisal 2013.
45. Godfrey C. Cost effectiveness of treatment for alcohol problems: findings of the randomised UK alcohol treatment trial (UKATT). BMJ 2005;331:544-8.
46. Heather N, Adamson SJ, Raistrick D, et al. Initial preference for drinking goal in the treatment of alcohol problems: I. Baseline differences between abstinence and non-abstinence groups. Alcohol Alcohol 2010;45:128-35.
47. Luquiens A, Reynaud M, Falissard B, et al. Quality of life among alcohol-dependent patients: how satisfactory are the available instruments? A systematic review. Drug Alcohol Depend 2012;125:192-202.